Eun Gyeong Seol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eun Gyeong Seol has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Min Jung Kim
Department of Pediatrics, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin-si, Republic of Korea
2 shared publications - Yu-Jin Kwon
Department of Family Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
2 shared publications - Eunju Lee
Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul 06273, Republic of Korea
1 shared publication - Heejung Kim
Department of Laboratory Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
1 shared publication - Hyangkyu Lee
Professor, College of Nursing · Mo-Im Kim Nursing Research Institute, Yonsei University, Seoul, Korea
1 shared publication - Hye Sun Lee
Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
1 shared publication
Latest Publications
- Open Access
Growth Patterns in Young Children with Food Allergy: A Matched Cross-Sectional and Longitudinal Study
Background/Objectives: Growth in young children with IgE-mediated food allergy (FA) remains unclear, particularly whether deficits are present at diagnosis or emerge during follow-up. We compared growth at diagnosis and subsequent growth trajectories between children with FA and healthy controls. Methods: We retrospectively analyzed children younger than 6 years with IgE-mediated FA (n = 176) and healthy controls (n = 340), each with at least two anthropometric records, at a single center in Korea. Children with FA were matched 1:1 to controls by age and sex using propensity scores (149 pairs). Height, weight, and body mass index (BMI) standard deviation scores (SDS) were calculated using the 2017 Korean National Growth Charts and compared using linear mixed models stratified by age at the first measurement (p = 0.005), with a significant between-group difference among children aged ≥1 year but not among those aged p = 0.044) and weight SDS (difference −0.263 SDS/year; p < 0.001) than infants allergic to egg or milk only. Conclusions: Despite comparable growth at diagnosis, children with IgE-mediated FA showed a steeper subsequent decline in height SDS. The clinical significance of this difference and the value of serial growth assessment or targeted nutritional management require prospective evaluation.
Open AccessGrowth Patterns in Young Children with Food Allergy: A Matched Cross-Sectional and Longitudinal Study
Background/Objectives: Growth in young children with IgE-mediated food allergy (FA) remains unclear, particularly whether deficits are present at diagnosis or emerge during follow-up. We compared growth at diagnosis and subsequent growth trajectories between children with FA and healthy controls. Methods: We retrospectively analyzed children younger than 6 years with IgE-mediated FA (n = 176) and healthy controls (n = 340), each with at least two anthropometric records, at a single center in Korea. Children with FA were matched 1:1 to controls by age and sex using propensity scores (149 pairs). Height, weight, and body mass index (BMI) standard deviation scores (SDS) were calculated using the 2017 Korean National Growth Charts and compared using linear mixed models stratified by age at the first measurement (p = 0.005), with a significant between-group difference among children aged ≥1 year but not among those aged p = 0.044) and weight SDS (difference −0.263 SDS/year; p < 0.001) than infants allergic to egg or milk only. Conclusions: Despite comparable growth at diagnosis, children with IgE-mediated FA showed a steeper subsequent decline in height SDS. The clinical significance of this difference and the value of serial growth assessment or targeted nutritional management require prospective evaluation.
- Open Access
Changing Trends of Respiratory Viruses in Hospitalized Children During and After the COVID-19 Emergency Phase in Yongin, South Korea (2020–22 vs. 2023–24)
The COVID-19 pandemic and subsequent non-pharmaceutical interventions (NPIs) significantly disrupted the epidemiology of pediatric respiratory viruses. This study compared infection patterns among 3658 hospitalized children in South Korea during the pandemic (2020–2022) and the post-emergency phase (2023–2024), following the relaxation of mandatory NPIs. Of 4419 eligible tests, the most frequently detected viruses overall were rhinovirus/enterovirus (HRV/HEV) (27.9%), influenza (14.5%), and respiratory syncytial virus (RSV, 11.9%). The post-emergency phase was marked by a dramatic surge in influenza virus (IFV), which surged dramatically (5.5% → 28.2%), and a more than two-fold increase in adenovirus (ADV) (5.7% → 12.5%) (p < 0.001). (p < 0.001). Conversely, parainfluenza virus (PIV) detection rates declined significantly (15.4% → 11.3%, p < 0.001). Demographically, post-emergency phase patients were significantly older (mean 4.9 vs. 3.5 years) and experienced a shorter hospital stays (3.2 vs. 4.3 days) (p < 0.001). Crucially, age-specific susceptibility shifts were evident. IFV rebounded across all pediatric ages but spiked severely in school-aged children and adolescents, while HRV/HEV demonstrated a clear proportional shift towards older age groups. These results demonstrate a substantial reconfiguration of the pediatric respiratory landscape, necessitating age-stratified surveillance and flexible public health strategies to mitigate the future infectious disease burden.
Open AccessChanging Trends of Respiratory Viruses in Hospitalized Children During and After the COVID-19 Emergency Phase in Yongin, South Korea (2020–22 vs. 2023–24)
The COVID-19 pandemic and subsequent non-pharmaceutical interventions (NPIs) significantly disrupted the epidemiology of pediatric respiratory viruses. This study compared infection patterns among 3658 hospitalized children in South Korea during the pandemic (2020–2022) and the post-emergency phase (2023–2024), following the relaxation of mandatory NPIs. Of 4419 eligible tests, the most frequently detected viruses overall were rhinovirus/enterovirus (HRV/HEV) (27.9%), influenza (14.5%), and respiratory syncytial virus (RSV, 11.9%). The post-emergency phase was marked by a dramatic surge in influenza virus (IFV), which surged dramatically (5.5% → 28.2%), and a more than two-fold increase in adenovirus (ADV) (5.7% → 12.5%) (p < 0.001). (p < 0.001). Conversely, parainfluenza virus (PIV) detection rates declined significantly (15.4% → 11.3%, p < 0.001). Demographically, post-emergency phase patients were significantly older (mean 4.9 vs. 3.5 years) and experienced a shorter hospital stays (3.2 vs. 4.3 days) (p < 0.001). Crucially, age-specific susceptibility shifts were evident. IFV rebounded across all pediatric ages but spiked severely in school-aged children and adolescents, while HRV/HEV demonstrated a clear proportional shift towards older age groups. These results demonstrate a substantial reconfiguration of the pediatric respiratory landscape, necessitating age-stratified surveillance and flexible public health strategies to mitigate the future infectious disease burden.
- Open Access
Assessing the Feasibility and Efficacy of Pre-Sleep Dim Light Therapy for Adults with Insomnia: A Pilot Study
Background: Insomnia is increasingly recognized for its marked impact on public health and is often associated with various adverse health outcomes, including cardiovascular diseases and mental health disorders. The aim of this study was to investigate the efficacy of pre-sleep dim light therapy (LT) as a non-pharmacological intervention for insomnia in adults, assessing its influence on sleep parameters and circadian rhythms. Methods: A randomized, open-label, two-arm clinical trial was conducted over two weeks with 40 participants aged 20–60 years, all of whom had sleep disorders (CRIS, KCT0008501). They were allocated into control and LT groups. The LT group received exposure to warm-colored light, minimizing the blue spectrum, before bedtime. The study combined subjective evaluation via validated, sleep-related questionnaires, objective sleep assessments via actigraphy, and molecular analyses of circadian clock gene expression in peripheral blood mononuclear cells. Baseline characteristics between the two groups were compared using an independent t-test for continuous variables and the chi-squared test for categorical variables. Within-group differences were assessed using the paired t-test. Changes between groups were analyzed using linear regression, adjusting for each baseline value and body mass index. The patterns of changes in sleep parameters were calculated using a linear mixed model. Results: The LT group exhibited significant improvements in sleep quality (difference in difference [95% CI]; −2.00 [−3.58, −0.43], and sleep efficiency (LT: 84.98 vs. control: 82.11, p = 0.032), and an advanced Dim Light Melatonin Onset compared to the control group (approximately 30 min). Molecular analysis indicated a significant reduction in CRY1 gene expression after LT, suggesting an influence on circadian signals for sleep regulation. Conclusions: This study provides evidence for the efficacy of LT in improving sleep quality and circadian rhythm alignment in adults with insomnia. Despite limitations, such as a small sample size and short study duration, the results underscore the potential of LT as a viable non-pharmacological approach for insomnia. Future research should expand on these results with larger and more diverse cohorts followed over a longer period to validate and further elucidate the value of LT in sleep medicine. Trial registration: The trial was registered with the Clinical Research Information Service (KCT0008501).
Open AccessAssessing the Feasibility and Efficacy of Pre-Sleep Dim Light Therapy for Adults with Insomnia: A Pilot Study
Background: Insomnia is increasingly recognized for its marked impact on public health and is often associated with various adverse health outcomes, including cardiovascular diseases and mental health disorders. The aim of this study was to investigate the efficacy of pre-sleep dim light therapy (LT) as a non-pharmacological intervention for insomnia in adults, assessing its influence on sleep parameters and circadian rhythms. Methods: A randomized, open-label, two-arm clinical trial was conducted over two weeks with 40 participants aged 20–60 years, all of whom had sleep disorders (CRIS, KCT0008501). They were allocated into control and LT groups. The LT group received exposure to warm-colored light, minimizing the blue spectrum, before bedtime. The study combined subjective evaluation via validated, sleep-related questionnaires, objective sleep assessments via actigraphy, and molecular analyses of circadian clock gene expression in peripheral blood mononuclear cells. Baseline characteristics between the two groups were compared using an independent t-test for continuous variables and the chi-squared test for categorical variables. Within-group differences were assessed using the paired t-test. Changes between groups were analyzed using linear regression, adjusting for each baseline value and body mass index. The patterns of changes in sleep parameters were calculated using a linear mixed model. Results: The LT group exhibited significant improvements in sleep quality (difference in difference [95% CI]; −2.00 [−3.58, −0.43], and sleep efficiency (LT: 84.98 vs. control: 82.11, p = 0.032), and an advanced Dim Light Melatonin Onset compared to the control group (approximately 30 min). Molecular analysis indicated a significant reduction in CRY1 gene expression after LT, suggesting an influence on circadian signals for sleep regulation. Conclusions: This study provides evidence for the efficacy of LT in improving sleep quality and circadian rhythm alignment in adults with insomnia. Despite limitations, such as a small sample size and short study duration, the results underscore the potential of LT as a viable non-pharmacological approach for insomnia. Future research should expand on these results with larger and more diverse cohorts followed over a longer period to validate and further elucidate the value of LT in sleep medicine. Trial registration: The trial was registered with the Clinical Research Information Service (KCT0008501).